Unnamed: 0,title,date,stock,sentiment
382251.0,"RBC Capital Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces Price Target of $35",2020-05-13 05:09:00-04:00,DRNA,neutral
382252.0,78 Biggest Movers From Yesterday,2020-05-12 05:02:00-04:00,DRNA,neutral
382253.0,"SunTrust Robinson Humphrey Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $33",2020-05-11 13:37:00-04:00,DRNA,neutral
382254.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,DRNA,neutral
382255.0,"Dicerna Pharmaceuticals Q1 EPS $(0.310) May Not Compare To $0.270 Estimate, Sales $34.028M May Not Compare To $59.830M Estimate",2020-05-07 16:53:00-04:00,DRNA,neutral
382256.0,Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer,2020-05-07 16:04:00-04:00,DRNA,neutral
382257.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,DRNA,negative
382258.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,DRNA,neutral
382259.0,"SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Raises Price Target to $38",2020-04-07 12:25:00-04:00,DRNA,neutral
382260.0,"H.C. Wainwright Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $32",2020-04-07 11:56:00-04:00,DRNA,neutral
382261.0,Alnylam and Dicerna Form a RNAi Therapeutics Collaboration on Alpha-1  Antitrypsin Deficiency-Associated Liver Disease,2020-04-06 07:12:00-04:00,DRNA,neutral
382262.0,Dicerna Provides Initial Observations From PHYOX3 Trial Of Nedosiran For Treatment Of Primary Hyperoxaluria,2020-03-31 07:33:00-04:00,DRNA,neutral
382263.0,Dicerna Pharma 8-K Shows Co. Plan To Address Business Continuity Amid Coronavirus Outbreak,2020-03-26 16:15:00-04:00,DRNA,neutral
382264.0,"Berenberg Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces $35 Price Target",2020-03-19 11:23:00-04:00,DRNA,neutral
382265.0,7 Stocks Moving In Wednesday's After-Hours Session,2020-03-18 17:05:00-04:00,DRNA,neutral
382266.0,Dicerna Receives Orphan Drug Designation From FDA For DCR-A1AT For Treatment Of Alpha-1 Antitrypsin Deficiency,2020-03-18 16:07:00-04:00,DRNA,neutral
382267.0,"Stifel Nicolaus Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $29",2020-02-28 10:37:00-05:00,DRNA,neutral
382268.0,"Dicerna Pharmaceuticals Q4 EPS $(0.58) Does Not Compare To $0.55 Estimate, Sales $7.08M Does Not Compare To $84.75M Estimate",2020-02-27 16:10:00-05:00,DRNA,neutral
382269.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,DRNA,positive
382270.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,DRNA,neutral
382271.0,"B. Riley FBR Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $30",2020-01-09 13:47:00-05:00,DRNA,neutral
382272.0,60 Biggest Movers From Friday,2019-12-23 05:37:00-05:00,DRNA,neutral
382273.0,40 Stocks Moving In Friday's Mid-Day Session,2019-12-20 12:07:00-05:00,DRNA,neutral
382274.0,"Dicerna Reports Closing Of Global Collab, Licensing Deal With Roche For Treatments For Chronic Hepatitis B Virus Infection",2019-12-19 07:39:00-05:00,DRNA,neutral
382275.0,10 Biggest Price Target Changes For Wednesday,2019-12-18 08:39:00-05:00,DRNA,neutral
382276.0,"Citigroup Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $39",2019-12-18 08:24:00-05:00,DRNA,neutral
382277.0,Dicerna Receives Orphan Drug Designation From European Commission For DCR-A1AT For Treatment Of Congenital Alpha-1 Antitrypsin Deficiency,2019-12-17 07:36:00-05:00,DRNA,neutral
382278.0,Stocks That Hit 52-Week Highs On Friday,2019-12-13 11:19:00-05:00,DRNA,neutral
382279.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,DRNA,positive
382280.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,DRNA,negative
382281.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,DRNA,neutral
382282.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,DRNA,neutral
382283.0,Stocks That Hit 52-Week Highs On Monday,2019-12-02 10:15:00-05:00,DRNA,neutral
382284.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,DRNA,positive
382285.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,DRNA,neutral
382286.0,10 Biggest Price Target Changes For Monday,2019-11-25 09:00:00-05:00,DRNA,neutral
382287.0,"Baird Maintains Outperform on Dicerna Pharmaceuticals, Raises Price Target to $50",2019-11-25 08:46:00-05:00,DRNA,neutral
382288.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,DRNA,positive
382289.0,77 Biggest Movers From Yesterday,2019-11-20 04:57:00-05:00,DRNA,neutral
382290.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-11-19 12:45:00-05:00,DRNA,neutral
382291.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,DRNA,neutral
382292.0,"H.C. Wainwright Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $30",2019-11-19 07:49:00-05:00,DRNA,neutral
382293.0,72 Biggest Movers From Yesterday,2019-11-19 04:39:00-05:00,DRNA,neutral
382294.0,44 Stocks Moving In Monday's Mid-Day Session,2019-11-18 12:32:00-05:00,DRNA,neutral
382295.0,Dicerna Pharmaceuticals shares are trading higher after the company entered into an agreement with Novo Nordisk to discover and develop RNAi Therapies for liver-related cardio-metabolic diseases.,2019-11-18 12:27:00-05:00,DRNA,positive
382296.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,DRNA,neutral
382297.0,Mid-Morning Market Update: Markets Edge Lower; United Bankshares To Buy Carolina Financial,2019-11-18 10:23:00-05:00,DRNA,positive
382298.0,"SunTrust Robinson Humphrey Assumes Dicerna Pharmaceuticals at Buy, Raises $24 Price Target",2019-11-18 09:33:00-05:00,DRNA,neutral
382299.0,"Dicerna, Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases",2019-11-18 06:01:00-05:00,DRNA,positive
382300.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,DRNA,negative
382301.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-14 10:09:00-05:00,DRNA,neutral
382302.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,DRNA,positive
382303.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,DRNA,neutral
382304.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,DRNA,neutral
382305.0,"Dicerna Pharmaceuticals Q3 EPS $(0.45) Misses $(0.28) Estimate, Sales $8.035M Miss $11.06M Estimate",2019-11-07 17:06:00-05:00,DRNA,negative
382306.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,DRNA,negative
382307.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,DRNA,neutral
382308.0,27 Stocks Moving In Thursday's Mid-Day Session,2019-10-31 11:51:00-04:00,DRNA,neutral
382309.0,15 Stocks Moving in Thursday's Pre-Market Session,2019-10-31 09:32:00-04:00,DRNA,neutral
382310.0,Dicerna Enters Agreement With Roche To Develop And Commercialize DCR-HBVS For The Treatment Of Chronic Hepatitis B Virus (HBV) Infection; Co. To Receive $200M Up Front Plus Up To $1.47B In Milestone Payments,2019-10-31 08:17:00-04:00,DRNA,positive
382311.0,"Benzinga's Top Upgrades, Downgrades For October 29, 2019",2019-10-29 10:49:00-04:00,DRNA,positive
382312.0,"Baird Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces $27 Price Target",2019-10-29 08:24:00-04:00,DRNA,neutral
382313.0,Baird Initiates Coverage On Dicerna Pharmaceuticals With Outperform Rating And $27 Price Target,2019-10-28 16:44:00-04:00,DRNA,neutral
382314.0,"Dicerna Pharmaceuticals Q2 EPS $(0.35) Misses $(0.31) Estimate, Sales $5.7M Miss $10.29M Estimate",2019-08-08 16:07:00-04:00,DRNA,negative
382315.0,Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1,2019-07-15 07:34:00-04:00,DRNA,neutral
382316.0,Dicerna To Begin Clinical Development Of DCR-A1AT For Treatment Of Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease,2019-07-02 07:07:00-04:00,DRNA,neutral
382317.0,Dicerna Highlights Presentation Of Additional Data From PHYOX1 Study Of DCR-PHXC In Patients With Primary Hyperoxaluria Type 1And Type 2,2019-06-21 07:32:00-04:00,DRNA,neutral
382318.0,5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential,2019-05-29 12:24:00-04:00,DRNA,neutral
382319.0,"Benzinga's Top Upgrades, Downgrades For May 24, 2019",2019-05-24 09:12:00-04:00,DRNA,positive
382320.0,"Citigroup Assumes Dicerna Pharmaceuticals, Inc. - Common Stock at Buy, Announces Price Target $30",2019-05-24 08:07:00-04:00,DRNA,neutral
382321.0,Dicerna Reports Dosing Of First Patient In Phase 1 Trial Of DCR-HBVS For Treatment Of Chronic Hep B Virus,2019-05-16 07:31:00-04:00,DRNA,neutral
382322.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,DRNA,positive
382323.0,"Dicerna Pharmaceuticals Q1 EPS $(0.38) Misses $(0.22) Estimate, Sales $3.107M Miss $10.3M Estimate",2019-05-09 17:09:00-04:00,DRNA,negative
382324.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,DRNA,neutral
382325.0,Dicerna Submits Updated IND Application For DCR-PHXC For Treatment Of Primary Hyperoxaluria For The PHYOX2 Pivotal Trial,2019-05-02 08:09:00-04:00,DRNA,neutral
382326.0,"Dicerna Pharma Highlights Presentation Of Updated Data Showing Utility Of DCR-PHXC In Treating PH1, PH2",2019-03-29 06:34:00-04:00,DRNA,neutral
382327.0,36 Stocks Moving In Tuesday's Pre-Market Session,2019-03-19 08:10:00-04:00,DRNA,neutral
382328.0,"Dicerna Pharmaceuticals Q4 EPS $(0.29) Misses $(0.22) Estimate, Sales $1.541M Miss $7.78M Estimate",2019-03-11 16:35:00-04:00,DRNA,negative
382329.0,"Earnings Scheduled For March 11, 2019",2019-03-11 04:17:00-04:00,DRNA,neutral
382330.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,DRNA,neutral
382331.0,Cowen & Co. Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating,2019-02-26 08:31:00-05:00,DRNA,neutral
382332.0,Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus,2019-01-28 07:31:00-05:00,DRNA,neutral
382333.0,"UPDATE: Dicerna Will Be Eligible To Receive Up To $170M In Potential Development, Commercial Milestones For Added Target",2019-01-04 06:19:00-05:00,DRNA,neutral
382334.0,Dicerna Pharma Reports Received Added Target Deal With Boehrniger Ingelheim For Upfront Payment Of $5M,2019-01-04 06:19:00-05:00,DRNA,neutral
382335.0,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake,2018-12-20 15:46:00-05:00,DRNA,neutral
382336.0,Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns',2018-11-28 13:05:00-05:00,DRNA,neutral
382337.0,"Leerink Swann Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces $24 Price Target",2018-11-28 08:53:00-05:00,DRNA,neutral
382338.0,"Leerink Initiates Coverage On Dicerna Pharma, Eidos Therapeutics, Intellia With Outperform Ratings, Alnylam, AvroBio, Ionis With Market Perform Ratings, REGENXBIO With Underperform",2018-11-27 17:24:00-05:00,DRNA,neutral
382339.0,7 Biggest Price Target Changes For Tuesday,2018-11-06 09:45:00-05:00,DRNA,neutral
382340.0,"Benzinga's Top Upgrades, Downgrades For November 6, 2018",2018-11-06 09:01:00-05:00,DRNA,positive
382341.0,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings,2018-11-06 07:41:00-05:00,DRNA,negative
382342.0,"B. Riley FBR Upgrades Dicerna Pharmaceuticals to Buy, Raises Price Target to $21",2018-11-06 06:42:00-05:00,DRNA,neutral
382343.0,B. Riley FBR Upgrades Dicerna Pharmaceuticals to Buy from Neutral; Raises Price Target to $21 from $13.50,2018-11-06 04:45:00-05:00,DRNA,neutral
382344.0,"Dicerna Pharmaceuticals Q3 EPS $(0.35) Misses $(0.25) Estimate, Sales $1.545M Miss $1.7M Estimate",2018-11-05 16:42:00-05:00,DRNA,negative
382345.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,DRNA,neutral
382346.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Oct. 29, 2018",2018-10-29 16:30:00-04:00,DRNA,positive
382347.0,42 Stocks Moving In Monday's Mid-Day Session,2018-10-29 12:21:00-04:00,DRNA,neutral
382348.0,Hearing Unconfirmed Chatter Citi has Increased its Price Target on Dicerna Pharma to $30,2018-10-29 11:36:00-04:00,DRNA,positive
382349.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Oct. 29, 2018",2018-10-29 10:13:00-04:00,DRNA,positive
382350.0,Mid-Morning Market Update: Markets Open Higher; IBM To Buy Red Hat In $34B Deal,2018-10-29 10:08:00-04:00,DRNA,neutral
382351.0,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",2018-10-29 09:31:00-04:00,DRNA,neutral
382352.0,"Dicerna Pharmaceuticals shares are trading up 30.2% premarket after the company announced a licensing and research collaboration with Eli Lilly to develop and commercialize new medicines in cardio-metabolic disease, neurodegeneration and pain.",2018-10-29 08:55:00-04:00,DRNA,negative
382353.0,30 Stocks Moving In Monday's Pre-Market Session,2018-10-29 08:25:00-04:00,DRNA,neutral
382354.0,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain",2018-10-29 06:08:00-04:00,DRNA,negative
382355.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,DRNA,negative
382356.0,"UPDATE: Dicerna To Receive $22M Upfront Payment, $15M Equity Investment And Potential For Added Milestone-Dependent, Royalty Payments",2018-10-24 06:41:00-04:00,DRNA,neutral
382357.0,"Alexion, Dicerna Report Collaboration To Discover, Develop RNAi Therapies For Complement-Mediated Diseases",2018-10-24 06:40:00-04:00,DRNA,neutral
382358.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,DRNA,neutral
382359.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,DRNA,neutral
382360.0,46 Biggest Movers From Yesterday,2018-09-14 04:40:00-04:00,DRNA,neutral
382361.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-13 13:12:00-04:00,DRNA,neutral
382362.0,Dicerna Pharmaceuticals shares are up 9.0% after Citigroup analysts earlier initiated coverage on the stock with a Buy Rating and $27 price target.,2018-09-13 12:21:00-04:00,DRNA,positive
382363.0,"Citigroup Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces $27 Price Target",2018-09-13 07:20:00-04:00,DRNA,neutral
382364.0,52 Biggest Movers From Friday,2018-09-10 05:21:00-04:00,DRNA,neutral
382365.0,44 Stocks Moving In Friday's Mid-Day Session,2018-09-07 12:54:00-04:00,DRNA,neutral
382366.0,Mid-Day Market Update: Dow Falls 150 Points; Dicerna Pharmaceuticals Shares Spike Higher,2018-09-07 12:30:00-04:00,DRNA,positive
382367.0,Mid-Morning Market Update: Markets Mixed; Genesco Beats Q2 Views,2018-09-07 10:15:00-04:00,DRNA,neutral
382368.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,DRNA,neutral
382369.0,55 Biggest Movers From Yesterday,2018-09-07 05:17:00-04:00,DRNA,neutral
382370.0,Dicerna Prices 7.6M Share Follow-On Public Offering of Common Stock @$13.02/Share,2018-09-07 04:00:00-04:00,DRNA,positive
382371.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-09-06 12:31:00-04:00,DRNA,neutral
382372.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,DRNA,neutral
382373.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,DRNA,positive
382374.0,Dicerna Announces 6.15M Shares Common Stock Follow-On Offering,2018-09-05 16:01:00-04:00,DRNA,positive
382375.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,DRNA,neutral
382376.0,"Dicerna Announces Proof Of Concept For DCR-PHXC In The Treatment Of Primary Hyperoxaluria; Initial Six-Week Data Show Significant And Sustained Reduction In Urinary Oxalate Levels, Detailed Readout Expected In Q4",2018-09-05 06:08:00-04:00,DRNA,positive
382377.0,"Stocks Which Set New 52-Week High Yesterday, August 15th",2018-08-16 10:22:00-04:00,DRNA,neutral
382378.0,"Benzinga's Top Upgrades, Downgrades For August 15, 2018",2018-08-15 09:10:00-04:00,DRNA,positive
382379.0,H.C. Wainwright Upgrades Dicerna Pharmaceuticals to Buy,2018-08-15 07:21:00-04:00,DRNA,neutral
382380.0,Dicerna Says Has Sufficient Cash To Fund Current Operating Plan Through 2019,2018-08-08 17:34:00-04:00,DRNA,neutral
382381.0,"Dicerna Pharmaceuticals Q2 EPS $(0.68) Misses $(0.42) Estimate, Sales $1.545M Miss $1.78M Estimate",2018-08-08 17:34:00-04:00,DRNA,negative
382382.0,Earnings Outlook For Dicerna Pharmaceuticals,2018-08-08 10:13:00-04:00,DRNA,neutral
382383.0,Dicerna Receives Recommendation From EMA Committee To Designate DCR-PHXC An Orphan Medicinal Product For Primary Hyperoxaluria In The EU,2018-07-11 07:31:00-04:00,DRNA,neutral
382384.0,"Jefferies Global Healthcare Begins Today, Presenters Include: Kadmon, Aeri Pharma, Chemed, Orthofix, Revance, Heron Therapeutics, and Dicerna Pharma",2018-06-05 08:55:00-04:00,DRNA,neutral
382385.0,"Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial, FDA Grants Orphan Drug Designation for DCR-PHXC for the Treatment of Primary Hyperoxaluria",2018-05-30 07:38:00-04:00,DRNA,positive
382386.0,Watching Dicerna Shares Amid Access Data Alert From FDA.gov Showing Orphan Drug Designation For Primary Hyperoxaluria Treatment,2018-05-17 16:04:00-04:00,DRNA,positive
382387.0,Dicerna Files For Mixed Shelf Offering Of Up To $250M,2018-05-17 06:16:00-04:00,DRNA,neutral
382388.0,Dicerna Says Believes Has Sufficient Cash To Fund Execution Of Current Plan Through '19,2018-05-14 16:19:00-04:00,DRNA,neutral
382389.0,"Dicerna Pharmaceuticals Q1 EPS $(0.30) Beats $(0.38) Estimate, Sales $1.545M Miss $1.87M Estimate",2018-05-14 16:18:00-04:00,DRNA,negative
382390.0,"Earnings Scheduled For May 14, 2018",2018-05-14 05:06:00-04:00,DRNA,neutral
382391.0,Dicerna Pharmaceuticals Shares Up 19.7% Following Settlement Of All Litigation With Alnylam,2018-04-20 14:58:00-04:00,DRNA,positive
382392.0,Hearing Evercore Raised Price Target On Dicerna From $14 To $17 On Settlement Announcement,2018-04-20 12:26:00-04:00,DRNA,neutral
382393.0,UPDATE: Dicerna To Pay To Alnylam Upfront Fee Of $2M Plus ~983K Shares Of DRNA; Will Also Pay Added $13M Over Next 4 Years,2018-04-20 12:14:00-04:00,DRNA,positive
382394.0,Dicerna Pharma Reports Settlement Of All Litigation With Alnylam,2018-04-20 12:13:00-04:00,DRNA,negative
382395.0,Dicerna Option Alert: May 18 $10 Calls at the Ask: 1000 @ $1.801 vs 20 OI; Earnings 5/7 After Close [est] Ref=$10.4019,2018-04-20 10:46:00-04:00,DRNA,positive
382396.0,40 Biggest Movers From Yesterday,2018-03-29 05:08:00-04:00,DRNA,neutral
382397.0,"Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation",2018-03-28 15:09:00-04:00,DRNA,positive
382398.0,"Benzinga's Top Upgrades, Downgrades For March 28, 2018",2018-03-28 09:31:00-04:00,DRNA,positive
382399.0,"B. Riley Initiates Coverage On Dicerna Pharmaceuticals with Neutral Rating, Announces $10.00 Price Target",2018-03-28 08:01:00-04:00,DRNA,neutral
382400.0,30 Stocks Moving In Friday's Mid-Day Session,2018-03-23 13:10:00-04:00,DRNA,neutral
382401.0,"Benzinga's Top Upgrades, Downgrades For March 23, 2018",2018-03-23 09:14:00-04:00,DRNA,positive
382402.0,H.C. Wainwright Downgrades Dicerna Pharmaceuticals to Neutral,2018-03-23 07:08:00-04:00,DRNA,neutral
382403.0,21 Stocks Moving In Thursday's Pre-Market Session,2018-03-22 08:24:00-04:00,DRNA,neutral
382404.0,33 Biggest Movers From Yesterday,2018-03-21 05:30:00-04:00,DRNA,neutral
382405.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-03-20 13:46:00-04:00,DRNA,neutral
382406.0,"Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point",2018-03-09 09:50:00-05:00,DRNA,positive
382407.0,Dicerna Pharma Says It Believes Co. Has Sufficient Cash To Fund Operations Through 2019,2018-03-08 16:08:00-05:00,DRNA,neutral
382408.0,"Dicerna Pharma Reports Q4 EPS $(0.90) vs $(0.77) Est., Sales $1.418M vs $1.36M Est.",2018-03-08 16:08:00-05:00,DRNA,neutral
382409.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,DRNA,neutral
382410.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,DRNA,neutral
382411.0,"Benzinga's Top Upgrades, Downgrades For February 5, 2018",2018-02-05 09:31:00-05:00,DRNA,positive
382412.0,"SunTrust Robinson Humphrey Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces $13.00 Price Target",2018-02-05 07:59:00-05:00,DRNA,neutral
382413.0,40 Biggest Movers From Yesterday,2018-01-24 05:38:00-05:00,DRNA,neutral
382414.0,33 Stocks Moving In Tuesday's Mid-Day Session,2018-01-23 12:50:00-05:00,DRNA,neutral
382415.0,"Evercore ISI Group Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces $14.00 Price Target",2018-01-16 09:41:00-05:00,DRNA,neutral
382416.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-01-10 08:03:00-05:00,DRNA,neutral
382417.0,"Dicerna Pharma Amended 13D Filing From RA Capital Shows Raised Stake From ~2.4M Shares As Of End Of Last Qtr. To ~5.07M Shares, Or 9.9% Stake",2017-12-20 17:39:00-05:00,DRNA,positive
382418.0,13D/A Filing Shows Bain Capital Life Sciences Fund Reporting 15.7% Stake In Dicerna Pharmaceuticals,2017-12-19 17:04:00-05:00,DRNA,neutral
382419.0,Dicerna Shares Down 9% Following Pricing Of ~5.71M Share Offering at $7/Share,2017-12-14 13:28:00-05:00,DRNA,positive
382420.0,Dicerna Prices Offering Of ~5.71M Shares At $7/Share,2017-12-14 09:29:00-05:00,DRNA,positive
382421.0,"Dicerna Reports Offering Of Common Stock, No Amount Disclosed",2017-12-13 16:45:00-05:00,DRNA,negative
382422.0,Dicerna Pharma Announces 1st Human Dosed In Phase 1 Trial Of DCR-PHXC,2017-12-07 09:38:00-05:00,DRNA,neutral
382423.0,StreetSweeper Issues New Short Report On Dicerna Pharmaceuticals,2017-11-20 10:58:00-05:00,DRNA,neutral
382424.0,40 Biggest Movers From Yesterday,2017-11-16 04:46:00-05:00,DRNA,neutral
382425.0,"Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics",2017-11-15 08:59:00-05:00,DRNA,neutral
382426.0,66 Biggest Movers From Yesterday,2017-11-03 04:49:00-04:00,DRNA,neutral
382427.0,"Dicerna Reports Q3 EPS $(0.92) vs $(0.69) Est., Sales $474K vs $20K Est.",2017-11-02 17:20:00-04:00,DRNA,neutral
382428.0,52 Stocks Moving In Thursday's Mid-Day Session,2017-11-02 12:29:00-04:00,DRNA,neutral
382429.0,Dicerna Option Alert: Jan 19 $7.5 Calls at the Ask: 1000 @ $0.7 vs 22 OI; Ref=$7.5,2017-11-02 12:02:00-04:00,DRNA,positive
382430.0,Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis,2017-11-02 08:46:00-04:00,DRNA,positive
382431.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-11-02 08:25:00-04:00,DRNA,neutral
382432.0,Dicerna Pharma Files Clinical Trial Application for DCR-PHXC,2017-10-16 07:33:00-04:00,DRNA,neutral
382433.0,Mid-Afternoon Market Update: KalVista Surges On Collaboration Deal With Merck; Izea Shares Plunge,2017-10-10 14:30:00-04:00,DRNA,positive
382434.0,12 Biggest Mid-Day Losers For Tuesday,2017-10-10 12:34:00-04:00,DRNA,negative
382435.0,"Dicerna Reports Q2 Loss/Share $(1.15) vs. $(0.60) Est., Sales $252K vs. $20K Est.",2017-08-10 16:13:00-04:00,DRNA,neutral
382436.0,"Dicerna Pharmaceuticals Reports Q1 EPS $(0.68) vs $(0.70) Est., Sales $133K vs $20K Est.",2017-05-08 16:59:00-04:00,DRNA,neutral
382437.0,Domain Partners VIII Reports 14.9% Stake In Dicerna Pharmaceuticals,2017-04-20 09:53:00-04:00,DRNA,neutral
382438.0,"What Success Is Made Of: Investors, Execs And Entrepreneurs Talk About Their Routines And Role Models - Part 2",2017-04-16 16:33:00-04:00,DRNA,positive
382439.0,"What Success Is Made Of: Investors, Execs And Entrepreneurs Talk Routines And Role Models",2017-04-10 15:33:00-04:00,DRNA,positive
382440.0,22 Stocks Moving In Monday's Pre-Market Session,2017-04-03 08:35:00-04:00,DRNA,neutral
382441.0,15 Biggest Mid-Day Gainers For Friday,2017-03-31 12:23:00-04:00,DRNA,neutral
382442.0,Dicerna Says Expects to Have Sufficient Cash to Fund the Execution of Co.'s Current Operations Into 2019,2017-03-30 16:08:00-04:00,DRNA,neutral
382443.0,"Dicerna Pharma Reports Q4 Loss $14M, $(0.68) vs $(0.73) Est., Sales $133K",2017-03-30 16:07:00-04:00,DRNA,negative
382444.0,"Earnings Scheduled For March 30, 2017",2017-03-30 04:45:00-04:00,DRNA,neutral
382445.0,How The Ultra-Wealthy Are Helping Advance Health And Life Sciences,2017-03-10 15:58:00-05:00,DRNA,positive
382446.0,Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gütermann,2017-03-08 15:43:00-05:00,DRNA,positive
382447.0,Family Office Legend Thomas Gütermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused On Pre-IPO Unicorns',2017-03-03 12:10:00-05:00,DRNA,positive
382448.0,"Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump",2017-02-22 14:36:00-05:00,DRNA,positive
382449.0,Exclusive: Dicerna CEO Discusses Financials And Institutional Investors,2017-02-16 09:40:00-05:00,DRNA,positive
382450.0,"Exclusive: Dicerna CEO Talks Products, Partnerships And Stock Performance",2017-02-15 13:54:00-05:00,DRNA,positive
382451.0,Exclusive: Dicerna CEO Explains RNA Interference And How It's Used To Treat Rare Genetic Diseases,2017-02-14 10:40:00-05:00,DRNA,positive
382452.0,Leerink Swann Initiates Coverage On Dicerna Pharmaceuticals To Market Perform,2017-01-31 08:40:00-05:00,DRNA,neutral
382453.0,Benzinga's Top Initiations,2016-12-12 09:49:00-05:00,DRNA,positive
382454.0,"H.C. Wainwright Initiates Coverage On Dicerna Pharmaceuticals at Buy, Announces $7.00 Target",2016-12-12 07:08:00-05:00,DRNA,neutral
382455.0,"Dicerna Pharmaceuticals Inc: FAMBROUGH DOUGLAS (Director,Chief Executive Officer) Buys 33,100 @ Avg Price: $3.71 (Form4)",2016-11-16 17:05:00-05:00,DRNA,neutral
382456.0,25 Stocks Moving In Wednesday's Pre-Market Session,2016-11-09 08:28:00-05:00,DRNA,neutral
382457.0,Dicerna Pharma Reports Q3 Net Loss $14.2M vs $16.9M in Same Qtr. Last Year; Outlook Reaffirmed,2016-11-07 16:49:00-05:00,DRNA,negative
382458.0,S-3 from Dicerna Pharma Shows Registration for $150M Mixed Securities Shelf Offering,2016-10-13 08:51:00-04:00,DRNA,positive
382459.0,"15 Stocks That Rallied For Three Days On Increasing Volume, No News",2016-10-03 07:53:00-04:00,DRNA,negative
382460.0,"Dicerna Prioritizes Resources to Advance GalXC Product Candidates, Clinical Development Discontinued For DCR-MYC In Oncology Indications",2016-09-26 07:33:00-04:00,DRNA,neutral
382461.0,10 Stocks With Three-Day Increasing Volume,2016-09-22 08:53:00-04:00,DRNA,neutral
382462.0,22 Stocks With Three-Day Increasing Volume,2016-09-21 09:16:00-04:00,DRNA,neutral
382463.0,30 Stocks With Three-Day Increasing Volume,2016-09-20 09:10:00-04:00,DRNA,neutral
382464.0,Dicerna Reports Q2 EPS $(0.75) vs. Est. $(0.84),2016-08-04 17:24:00-04:00,DRNA,neutral
382465.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-07-05 08:21:00-04:00,DRNA,neutral
382466.0,Dicerna Data Presentation Of GalXC To Occur At Investor Day Conf. Sees INDA Application In Late FY17,2016-06-29 08:07:00-04:00,DRNA,neutral
382467.0,Dicerna Reports Dosing of Initial Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1,2016-05-13 07:31:00-04:00,DRNA,neutral
382468.0,Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates,2016-05-11 07:35:00-04:00,DRNA,neutral
382469.0,Dicerna Reports Q1 EPS $(0.76) vs $(0.86) Est.,2016-05-09 17:11:00-04:00,DRNA,neutral
382470.0,"Dicerna Announces Appointment of John ""Jack"" Green as CFO",2016-04-18 16:10:00-04:00,DRNA,neutral
382471.0,"Dicerna Names John ""Jack"" Green CFO",2016-04-18 16:07:00-04:00,DRNA,neutral
382472.0,"Chardan Capital Initiates Coverage on Dicerna Pharmaceuticals at Neutral, Announces $5.00 PT",2016-04-04 16:46:00-04:00,DRNA,neutral
382473.0,8 Stocks Moving In Tuesday's After-Hours Session,2015-12-29 16:45:00-05:00,DRNA,neutral
382474.0,"Dicerna Initiates Dosing For First Healthy Volunteer Clinical Trial For Primary Hyperoxaulria Type 1 Treatment, Expects TO Start Phase 1 Trial In Patients By Early 2016",2015-12-21 16:12:00-05:00,DRNA,positive
382475.0,Dicerna Updates Progress on the Development of DCR-MYC for the Solid Tumor Treatment,2015-12-21 16:06:00-05:00,DRNA,positive
382476.0,"Dicerna Pharmaceuticals Names John ""Jack"" Green Interim CFO",2015-12-15 18:57:00-05:00,DRNA,neutral
382477.0,Dicerna Reports Q3 EPS $(0.82) vs. Est. $(0.84),2015-11-10 16:09:00-05:00,DRNA,neutral
382478.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,DRNA,neutral
382479.0,Cowen & Company Initiates Coverage on Dicerna Pharmaceuticals at Outperform,2015-09-08 06:55:00-04:00,DRNA,neutral
382480.0,"Dicerna Pharmaceuticals Submits Investigational New Drug (IND) Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)",2015-09-02 07:30:00-04:00,DRNA,neutral
382481.0,"EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)",2015-08-06 19:13:00-04:00,DRNA,positive
382482.0,Dicerna Reports Q2 EPS $(0.72) vs. Est. $(0.78),2015-08-06 18:12:00-04:00,DRNA,neutral
382483.0,Dicerna Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2015-07-01 07:24:00-04:00,DRNA,positive
382484.0,Dicerna Issues Response To Alnylam Complaint,2015-06-11 07:30:00-04:00,DRNA,negative
382485.0,"MaxLinear, PowerSecure, Alaska Air Lead After-Hours Movers To Close The Week",2015-06-06 14:40:00-04:00,DRNA,neutral
382486.0,Benzinga's Top Initiations,2015-05-29 09:25:00-04:00,DRNA,positive
382487.0,Jefferies Initiates Dicerna Pharmaceuticals At Buy,2015-05-29 08:28:00-04:00,DRNA,neutral
382488.0,"Jefferies Initiates Coverage on Dicerna Pharmaceuticals at Buy, Lowers $25.00 PT",2015-05-29 07:17:00-04:00,DRNA,negative
382489.0,Morning Market Losers,2015-05-21 09:59:00-04:00,DRNA,negative
382490.0,Benzinga's Top #PreMarket Losers,2015-05-21 08:15:00-04:00,DRNA,negative
382491.0,Dicerna Prices 2.75M Share Offering @$17.75/Share,2015-05-20 20:32:00-04:00,DRNA,positive
382492.0,Dicerna Reports Follow-On Offering of 2.75M Shares,2015-05-18 16:07:00-04:00,DRNA,positive
382493.0,Dicerna Reports Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs),2015-05-14 07:33:00-04:00,DRNA,positive
382494.0,Dicerna Pharma Reports Q1 Loss $0.79 Vs Est Loss $0.73,2015-05-11 16:05:00-04:00,DRNA,negative
382495.0,Dicerna Pharma Announces FDA Has Granted Orphan Drug Designation for DCR-PH1 for Treatment of PH1,2015-04-23 16:58:00-04:00,DRNA,positive
382496.0,FDA Grants Orphan Drug Designation for Dicerna's DCR-PH1,2015-04-23 16:58:00-04:00,DRNA,positive
382497.0,Biotech Investors: May 29th Could Be A Big Day,2015-04-21 14:39:00-04:00,DRNA,neutral
382498.0,Dicerna Presents New β-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting,2015-04-10 08:01:00-04:00,DRNA,negative
382499.0,Dicerna Reports Q4 Adj. EPS $(0.57) vs. Est. $(0.57),2015-03-12 16:12:00-04:00,DRNA,neutral
382500.0,Dicerna Pharma Announces First Patient Dosing,2015-02-02 07:31:00-05:00,DRNA,neutral
382501.0,Dicerna Receives US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads,2015-01-12 07:47:00-05:00,DRNA,neutral
382502.0,Dicerna Pharmaceuticals Presents Positive Preclinical Data On Its DsiRNA Therapeutics Targeting MYC and β-Catenin at AACR MYC,2015-01-12 07:46:00-05:00,DRNA,positive
382503.0,UPDATE: Dicerna Announces License Agreement With Tekmira,2014-11-17 08:09:00-05:00,DRNA,positive
382504.0,Dicerna Announces License Agreement With Tekmira,2014-11-17 08:05:00-05:00,DRNA,positive
382505.0,UPDATE: Stifel Reiterates On Dicerna Pharmaceuticals As DCR-MYC Is Progressing Nicely,2014-11-07 09:10:00-05:00,DRNA,positive
382506.0,"Stifel Nicolaus Maintains Buy on Dicerna Pharmaceuticals, Lowers PT to $21.00",2014-11-07 07:40:00-05:00,DRNA,negative
382507.0,Dicerna Pharmaceuticals Reports Q3 EPS of $(0.54) vs $(0.63) Est,2014-11-06 07:21:00-05:00,DRNA,neutral
382508.0, Dicerna Pharmaceuticals Expects to Initiate Phase 1 Trial of DCR-PH1 in 2015,2014-11-06 07:18:00-05:00,DRNA,neutral
382509.0,Dicerna Presents Preclinical Data for Investigational RNAi Therapeutic DCR-PH1 in Primary Hyperoxaluria Type 1 (PH1) at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society ,2014-10-14 17:34:00-04:00,DRNA,neutral
382510.0,Dicerna Announces Multiple Patents Covering Claims for Dicer Substrate siRNAs ,2014-08-21 10:06:00-04:00,DRNA,neutral
382511.0,Benzinga's Volume Movers,2014-06-30 10:26:00-04:00,DRNA,neutral
382512.0,Morning Market Movers ,2014-06-30 09:40:00-04:00,DRNA,neutral
382513.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,DRNA,neutral
382514.0,"Top Healthcare Movers For June 9, 2014",2014-06-09 14:27:00-04:00,DRNA,positive
382515.0,"Stifel Nicolaus Maintains Buy on Dicerna Pharmaceuticals, Lowers PT to $44.00",2014-05-14 06:34:00-04:00,DRNA,negative
382516.0,Dicerna Pharma Reports Q1 Adj. Loss of $0.56/Share,2014-05-13 16:14:00-04:00,DRNA,negative
382517.0,Dicerna Pharmaceuticals Reports Q1 EPS of $(1.02) vs $(0.52) Est,2014-05-13 16:06:00-04:00,DRNA,neutral
382518.0,Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC ,2014-04-16 16:18:00-04:00,DRNA,neutral
382519.0,Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical Officer,2014-04-02 16:05:00-04:00,DRNA,neutral
382520.0,Stocks Hitting 52-Week Lows,2014-04-02 10:27:00-04:00,DRNA,negative
382521.0,UPDATE: Stifel Initiates Coverage on Dicerna Pharmaceuticals on Riding the RNAi Wave,2014-02-24 10:02:00-05:00,DRNA,neutral
382522.0,Benzinga's Top Initiations,2014-02-24 08:41:00-05:00,DRNA,positive
382523.0,"Stifel Nicolaus Initiates Coverage on Dicerna Pharmaceuticals at Buy, Announces $53.00 PT",2014-02-24 08:25:00-05:00,DRNA,neutral
382524.0,"Jefferies Initiates Coverage on Dicerna Pharmaceuticals at Buy, Announces $48.00 PT",2014-02-24 07:45:00-05:00,DRNA,neutral
382525.0,Financial Times Reports Large Number of US Biotech IPOs Could Indicate Bubble is Near,2014-02-09 10:35:00-05:00,DRNA,positive
382526.0,"UPDATE: Dicerna Shares Rise as High as $34.81 on IPO, Currently Trading Around $30",2014-01-30 11:09:00-05:00,DRNA,positive
382527.0,Dicerna Pharmaceuticals Shares Resume After Circuit Breaker Halt,2014-01-30 11:06:00-05:00,DRNA,positive
382528.0,Dicerna Prices 6M Share IPO at $15.00/Share,2014-01-30 05:46:00-05:00,DRNA,positive
382529.0,Dicerna Pharmaceuticals Raises IPO to 6M Shares from 5M ,2014-01-28 11:47:00-05:00,DRNA,positive
